Teva Pharmaceutical Industries CEO Erez Vigodman on Thursday vowed to press ahead with the company’s $82-per-share bid to buy local generic drug giant Mylan even though Mylan’s board has thus far rebuffed the offer.

“We are confident that the combination of Teva and Mylan makes strategic and financial sense with our proposal representing a full and fair price for Mylan and its stockholders,” Mr. Vigodman told analysts during the Israel-based generic drug company’s first-quarter earnings call.

“We are prepared to devote all necessary resources to complete this combination,” he said. “We are committed to getting this done.”

Mylan has said it plans to remain independent as it pursues its own takeover of over-the-counter drug specialist Perrigo, which Wednesday rejected Mylan’s advances for a third time.

Advertise with us

Some analysts believe Teva will ultimately prevail, and they expect the company to raise its more than $40 billion offer.

“We continue to believe this wealth-creating transaction will occur,” Cowen and Co. analyst Ken Cacciatore wrote in a report to clients earlier this week after Mylan formally rejected Teva.

Mylan chairman Robert Coury’s contention that the starting point for any merger discussions with Mylan would have to be well in excess of $100 per share “is fairly fanciful,” Mr.Cacciatore said.

“We continue to believe that Mylan shareholders have a very realistic view of their assets, which is likely closer to $88-$92” per share, he said.

Canaccord Genuity analyst Corey Davis said he believes Teva’s overtures are “starting to resonate” with Mylan shareholders.

Advertise with us

“Eventually, the Mylan board is going to have to negotiate with Teva if [shareholders] put enough pressure” on the company, he said in an email.

Mr. Davis said Mylan needs to make a substantially better offer to win Perrigo.

“Not sure why Robert [Coury] even bothered” to make the latest bid for Perrigo, he said. “Everyone could have predicted the rejection.

“It’s starting to look silly.”

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.